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Spinocerebellar ataxia type 1 (SCA1) is one of
nine inherited, typically adult onset, polyglut-
amine neurodegenerative diseases. To exam-
ine whether development impacts SCA1, we
used a conditional transgenic mouse model of
SCA1 to delay the postnatal expression of mu-
tant ATXN1 until after completion of cerebellar
development. Delayed postnatal expression of
mutant ATXN1 led to a substantial reduction in
severity of disease in adults in comparison
with early postnatal gene expression. This was
linked to a destabilization of RORa, a transcrip-
tion factor critical for cerebellar development. In
SCA1 mice, there was a depletion of RORa and
a reduction in expression of genes controlled by
RORa. Partial loss of RORa enhanced mutant
ATXN1 pathogenicity. Additionally, evidence
points to the existence of a complex containing
ATXN1, RORa, and the RORa coactivator
Tip60. These studies indicate RORa and Tip60
have a role in SCA1 and suggest a mechanism
by which compromising cerebellar develop-
ment contributes to severity of neurodegenera-
tion in an adult.
INTRODUCTION
Spinocerebellar ataxia type 1 (SCA1) is one of nine in-
herited diseases known as polyglutamine neurodegenera-
tive disorders (Zoghbi and Orr, 2000; Taylor et al., 2002).
The mutational mechanism of these diseases is the ex-
pansion of a CAG trinucleotide repeat that encodes apolyglutamine stretch within each respective disease-
causing protein. Typical of the autosomal dominant
ataxias, SCA1 is characterized by a progressive loss of
motor coordination, speech impairment, and problems
with swallowing. Although the SCA1 encoded protein
ATAXIN 1 (ATXN1) is widely expressed (Servadio et al.,
1995; Banfi et al., 1996), in SCA1, mutant ATXN1 causes
neurodegeneration predominantly of cerebellar Purkinje
cells and neurons in the brain stem and spinal cord (Clark
and Orr, 2000).
Studies utilizing animal models have provided consider-
able insight into mechanisms of pathogenesis. Sca1 null
mice fail to develop ataxia and Purkinje cell pathology
(Matilla et al., 1998). In contrast, mice that either overex-
pressmutant ATXN1 ormice that have a targeted insertion
of 154 repeats into the endogenous Sca1 locus develop
ataxia and Purkinje cell pathology similar to that seen in
SCA1 patients (Burright et al., 1995; Watase et al.,
2002). Transgenic mouse studies demonstrated that while
mutant ATXN1 must enter the nucleus of Purkinje cells to
cause disease, formation of the inclusions per se was not
required for the initiation of disease (Klement et al., 1998).
Further, misfolding and impaired degradation of mutant
ATXN1 likely contributes to pathogenesis (Cummings
et al., 1998, 1999, 2001). Phosphorylation of Ser776 inmu-
tant ATXN1 is important for pathogenesis (Emamian et al.,
2003), likely because this modification of ATXN1 is in-
volved in its stabilization by regulating its interaction with
the cellular protein 14-3-3 (Chen et al., 2003). Specific
genes whose expression is downregulated prior to the on-
set of pathology were identified (Lin et al., 2000; Serra
et al., 2004). Several nuclear proteins that interact with
ATXN1 have been identified as possible mediators of
SCA1 pathogenesis, including PQBP, SMRT, BOAT, and
Gfi-1 (Okazawa et al., 2002; Tsai et al., 2004; Tsuda
et al., 2005). Yet, even with these advances, the molecular
mechanism by which a mutant ATXN1-induced alterationCell 127, 697–708, November 17, 2006 ª2006 Elsevier Inc. 697
in gene expression results in the degeneration of only cer-
tain neurons, such as cerebellar Purkinje cells, remains
unknown. Here we show that developmental timing of mu-
tant SCA1 expression has a substantial impact upon dis-
ease and suggest a mechanism by which mutant ATXN1
compromises cerebellar development and, thus, contrib-
utes to severity of neurodegeneration in adult mice.
RESULTS
Expression of Mutant ATXN1 during Cerebellar
Development Enhances Disease
In the original series of SCA1[82Q] transgenic mice, one
line, designated B04, stood out as having a relatively low
level of SCA1 expression yet developed a severe ataxia
(Figure S1; Burright et al., 1995). An interesting feature of
SCA1 expression in line B04 is that it began on postnatal
day 2. In the other SCA1[82Q] lines, exemplified by line
B05, transgene expression begins during postnatal week
2 (days P10–P14).
Since the first 3 postnatal weeks are a critical period for
Purkinje cell and cerebellar cortex development in the
mouse (Goldowitz and Hamre, 1998), we hypothesized
that the increased susceptibility to mutant ATXN1 in
SCA1[82Q] B04 mice might be due to expression of the
SCA1[82Q] transgene for a greater portion of the critical
period of postnatal development. The availability of
a doxycycline-regulated conditional transgenic mouse
model of SCA1 (Zu et al., 2004) allowed us to test this idea.
The strategy utilized was to compare disease in two
groups of conditional SCA1[82Q] transgenic mice. Both
groups were exposed to mutant ATXN1 expression for
a total of 12 weeks. In one group, the 12 week gene-on
group, SCA1 transgene expression was allowed to begin
during postnatal week 2. In the second group SCA1 trans-
gene expression was delayed for 14 weeks, until well after
the cerebellum had matured, and then turned on for 12
weeks. The time course of SCA1 transgene expression
in each group of mice was confirmed by northern blot
analysis (Figure 1A). In the 12 week gene-on mice, SCA1
mRNA was first detectable at day P3, reaching the maxi-
mum level of expression by day P10. In the 14 week
gene-off/12 week gene-on mice, expression of the SCA1
transgene was suppressed for 14 weeks. By 2 days after
removing doxycycline, the SCA1 transgene reached
a maximum level of expression similar to the maximum
level of expression seen with the 12 week-gene-on mice.
Disease severity in the 12 week gene-on mice and the
14 week gene-off/12 week gene-on mice was assessed
using both neurological and pathological criteria. By
home cage behavior, the 12 week gene-on SCA1[82Q]
mice had amoderate level of ataxia as reported previously
(Zu et al., 2004). In contrast, the 14week gene-off/12 week
gene-on SCA1[82Q]mice showed no signs of ataxia. Con-
sistent with the home cage behavior observations, the 14
week gene-off/12 week gene-on mice performed mark-
edly better on the accelerating Rotarod than did the 12
week gene-on mice (Figure 1B).698 Cell 127, 697–708, November 17, 2006 ª2006 Elsevier Inc.Purkinje cell pathology in both the 14 week gene-off/12
week gene-on SCA1[82Q]mice and the 12 week gene-on
SCA1[82Q] mice was quantified by measuring the thick-
ness of the molecular layer (Zu et al., 2004). This measure-
ment assesses the degree of dendritic atrophy character-
istic of disease in SCA1[82Q] transgenic mice. The milder
neurological phenotype seen in 14week gene-off/12week
gene-onSCA1[82Q]micewasaccompaniedbya substan-
tially reduced level of Purkinje cell pathology (Figures 1C
and 1D). The thickness of the cerebellar molecular layer
measured in the 14 week gene-off/12 week gene-on
SCA1[82Q] mice was greater, comparable to wild-type
mice, than the thickness of the molecular layer seen in
the 12 week gene-on SCA1[82Q] mice (Figure 1D). This
milder Purkinje cell pathology continued to be observed
when the 14 week gene-off/gene-on SCA1[82Q] mice
were allowed to age further with the gene-on period ex-
tended to 24 weeks (Figure 1E). In 14 week gene-off/24
week gene-on mice, the thickness of the molecular layer
remained greater than the molecular layer in mice where
SCA1[82Q] was expressed for 24 weeks straight.
To further focus on the critical period where the lack of
mutant ATXN1 expression seems to protect Purkinje cells
from the effects of subsequent expression of mutant
ATXN1, we generated mice where SCA1[82Q] was ex-
pressed for 12 weeks following off periods of either the
first 2 or 3 postnatal weeks. At both the primary fissure
and a posterior fissure, gene-off periods for the first 2
and 3 postnatal weeks also had a protective effect on
the thickness of the molecular layer (Figure 1D).
These data indicate that the timing of mutant ATXN1 ex-
pressed during the first postnatal weeks, i.e., during a crit-
ical period of cerebellar development and maturation,
modifies subsequent disease severity in the adult. One
potential explanation for this developmental effect on
SCA1 severity is that ATXN1 interacts with a pathway in-
volved in Purkinje cell development.
RORa-Regulated Genes Are Downregulated
in the Cerebella of SCA1[82Q] Mice
Previously, using a subtractive cDNA approach (Lin et al.,
2000) as well as a microarray-based gene profiling strat-
egy (Serra et al., 2004), we identified four genes whose ex-
pression is regulated by RORa (Gold et al., 2003). Subse-
quently, we analyzed the SCA1 gene-profile data set with
a set of analytical programs specifically designed for mi-
croarray data. This analysis yielded an expanded SCA1-
selected set of 53 genes, 13 of which increased in expres-
sionwith disease and 40 of which decreased in expression
with disease (Table S1).
When the set of 40 genes with a decreased expression
in 5week-oldSCA1[82Q]micewas compared to the entire
set of RORa-mediated genes generated by Gold et al.
(2003), considerable overlap was found (Table 1). Among
the RORa-responsive genes in the SCA1 gene set were all
four of the genes to which RORa has been found to bind
directly to their promoters in vivo (Gold et al., 2003). These
data indicated that RORa-mediated genes are, as a group,
Figure 1. Mutant ATXN1 Levels during Cerebellar Development Modify Disease
(A) Northern blot analysis of SCA1[82Q] transgene RNA expression in the12 week SCA1[82Q] gene-on mice and the 14 week SCA1[82Q] gene-off/12
week SCA1[82Q] gene-on mice.
(B) Rotarod performance (mean ± SEM) for 12 week SCA1[82Q] gene-on mice and 14 week SCA1[82Q] gene-off/12 week SCA1[82Q] gene-on mice.
*Significant p values (student’s t test) were obtained for day 1 (p = 0.04) and day 4 (p = 0.03). The p values for day 2 and day 3 were 0.05 and 0.07,
respectively.
(C) Calbindin immunostaining depicting the atrophy of Purkinje cell dendrites in the 14weekSCA1[82Q] gene-off/12 weekSCA1[82Q] gene-on and 12
week SCA1[82Q] gene-on mice.
(D) Purkinje cell dendritic atrophy (molecular layer thickness, mean ± SEM) in the various cohorts of conditional SCA1[82Q]. To assess statistical sig-
nificance, a one-way ANOVA was performed followed by a Tukey Honestly Significant Difference (HSD) Test when necessary.
(E) Thickness of the molecular layer in mice aged for 24 weeks with the transgene on following a 12 week gene-off period (12 week SCA1[82Q] gene-
off/24 week SCA1[82Q] gene-on mice) compared to 24 week SCA1[82Q] gene-on mice.downregulated at an early stage of disease in Purkinje
cells of SCA1[82Q] mice.
RORa Is Decreased in Purkinje Cells
of SCA1[82Q] Transgenic Mice
To examine whether a decrease in RORa might be the
cause of the decrease in RORa-mediated gene expres-Csion seen in cerebella from the SCA1 mice, we used im-
munofluorescence to assess RORa expression. Figure 2A
shows the level of RORa immunostaining in the nuclei of
wild-type mouse Purkinje cells as well as the level of stain-
ing in the nuclei of specific interneurons in the molecular
layer. In contrast, the levels of RORa staining in Purkinje
cell nuclei in a 12 week-old SCA1[82Q] heterozygousell 127, 697–708, November 17, 2006 ª2006 Elsevier Inc. 699
Table 1. Overlap between SCA1[82Q] and Staggerer (RORa) Gene Sets
GENE PROTEIN
Staggerer SCA1[82Q]
Microarray Q-PCR Microarray Q-PCR
Calb1 calbindin-28K, Ca+2 binding protein Z Z
**Itpr1** inositol 1,4,5-triphosphate receptor 1 Z Z Z
**Slc1a6** EAAT4, glutamate transporter Z Z Z
**Pcp2 (L7)** GoLoco G protein modulatory domain Z Z Z
Rora RAR-related orphan Receptor a Z Z
Kit1 kit ligand Z Z
**Pcp4** calmodulin inhibitor Z Z Z
Spnb3 brain-specific b-spectrin III Z Z
Idb2 inhibitor of DNA binding 2 Z Z
Grm1 mGluR1 glutamate receptor subunit Z Z
Atp2a2 SERCA2, Ca+2-transporting ATPase Z Z
Cals1 CARP, an Itpr1 binding protein Z Z Z
Homer2 5 5
** **Genes to which RORa binds to the promoter (Gold et al., 2003).mouse (Figure 2B) was noticeably less than RORa staining
in the nuclei of wild-type Purkinje cells. Sca1/ mice
(Figure 2C) and mice overexpressing a wild-type allele of
SCA1 (Figure 2D) had levels of RORa in their Purkinje cells
that appeared similar to those seen in wild-type mice. To
quantitatively assess the levels of RORa, we determined
the mean pixel density of RORa-positive Purkinje cell
and interneuron nuclei (Figure 2E). This analysis showed
that there were significant decreases in the levels of
RORa in the Purkinje cell nuclei of SCA1[30Q] and
SCA1[82Q] compared to wild-type mice.
To obtain a more quantitative assessment of RORa
levels, we performed western blot analyses. As a specific-
ity control, the amount of RORa in a cerebellar lysate pre-
pared from a staggerer (sg/sg) mouse, a null mutation at
Rora (Hamilton et al., 1996), was determined and found
to be negligible compared to the level of RORa in cerebel-
lar lysate from a wild-type mouse (Figure 3A, lane 1 versus
lane 8). Compared to the level of RORa in a lysate from
a wild-type mouse, the amount of RORa in a lysate from a
12 week-old mouse expressing a conditional SCA1[82Q]
allele was decreased significantly (Figure 3A, lane 4). Im-
portantly, when the conditional SCA1[82Q] allele was
turned off, RORa levels returned to normal by 2 days
(Figure 3A, lane 5). To confirm that the restoration of
RORa expression occurred within Purkinje cell nuclei,
we used immunofluorescence to examine RORa expres-
sion within 5 days of shutting off SCA1 expression in the
conditional SCA1[82Q] transgenic mice (Figures 3B and
3C). Mice lacking expression of the endogenous Sca1
gene, Sca1/ mice, had levels of RORa by western
blot analysis similar to those seen in wild-type mice
(Figure 3A, lane 3). Normal levels of RORawere also found
in mice expressing a form of ATXN1 with 82 glutamines,700 Cell 127, 697–708, November 17, 2006 ª2006 Elsevier IncATXN1[82Q]-K772T (Figure 3A, lane 2), that does not
cause disease due to amutation in the nuclear localization
sequence preventing the protein from entering the nu-
cleus (Klement et al., 1998). Moreover, mice overexpress-
ing wild-type ATXN1, ATXN1[30Q], also had levels of
RORa similar to nontransgenic wild-type mice (Figure 3A,
lane 7). Thus, decreased levels of RORawere found only in
cerebellar extracts frommice expressing a mutant form of
ATXN1 that caused ataxia.
To gain insight into the molecular basis for the loss of
RORa from Purkinje cell nuclei in the presence of mutant
ATXN1, northern blots were performed. As shown in
Figure 3D, the amount of RORa mRNA in a SCA1[82Q]
cerebellum was decreased compared to wild-type,
SCA1[30Q], or Sca1/ mice. Thus, in the presence of
mutant ATXN1, both RORa protein and mRNA levels
were reduced. The conditional SCA1[82Q] mice were
used to assess the relative contributions of RNA-based
and protein-based mechanisms to the mutant ATXN1-in-
duced decrease in RORa. The cerebellar levels of RORa
protein and mRNA in 12 week gene-on mice were com-
pared with those from 12 week gene-on/2 day gene-off
mice. The results (Figure 3E) show that after turning the
SCA1[82Q] gene off for 2 days the RORa protein was re-
stored in absence of a restoration of the RORa-mRNA
level. This result is consistent withmutant ATXN1 affecting
RORa protein levels independent of its effect on RORa-
mRNA levels.
Partial Loss of RORa Enhances the Pathogenicity
of ATXN1[82Q] in Transgenic Mice
To evaluate the role of RORa in SCA1 pathogenesis in vivo
using a genetic approach, we assessed the effect of a
loss-of-function allele of Rora in Purkinje cells by placing.
theSCA1[82Q] transgene on a sg/+ background that lacks
one functional copy of Rora. It is important to note that
this approach is complicated by the fact that the Pcp2
promoter directing Purkinje cell expression of the
SCA1[82Q] transgene is regulated by RORa (Gold et al.,
2003). The prediction would be that loss of function at
Rora would result in a decrease in ATXN1[82Q] expres-
sion, which by itself would lead to a less severe form of
disease.
Therefore, mice homozygous for Pcp2-SCA1[82Q]
were crossed onto the sg/+ background. As predicted,
mice homozygous forPcp2-SCA1[82Q] and heterozygous
for sg expressed a reduced level of SCA1[82Q] compared
to homozygous Pcp2-SCA1[82Q] mice on a wild-type
background (Figure 4A). The amount of SCA1[82Q] ex-
pressed by the homozygous SCA1[82Q]:sg/+ mice was
comparable to SCA1[82Q] expressed by heterozygous
SCA1[82Q] mice on a wild-type background. Thus, to as-
Figure 2. Purkinje Cell Expression of RORa in SCA1 Trans-
genic Mice
(A) Immunofluorescent staining of RORa in the cerebellar cortex of a 12
week-old wild-type (wt) FVB/nmouse. The box indicates Purkinje cells.
(B) Immunofluorescent staining of RORa in the cerebellar cortex of a 12
week-old SCA1[82Q] transgenic mouse.
(C) Immunofluorescent staining of RORa in the cerebellar cortex of a 12
week-old Sca1/ mouse. Section was simultaneously stained with
antibodies against RORa (red) and the Purkinje cell-marker calbindin
(green).
(D) Immunofluorescent staining of RORa in the cerebellar cortex of a 12
week-old SCA1[30Q] transgenic mouse.
(E) Quantitative analysis of the immunofluorescence data in panels
(A)–(D) (mean ± SEM).Csess the effect of a partial loss of RORa function on SCA1,
the disease status in heterozygous SCA1[82Q] mice on
a wild-type background was compared to the level of dis-
ease in the homozygous SCA1[82Q]:sg/+ mice. Figure 4B
shows that Purkinje cell pathology in the homozygous
SCA1[82Q]:sg/+ mice at 20 and 24 weeks of age was
more severe than the pathology seen in heterozygous
SCA1[82Q] mice. These results indicate that there is a
genetic interaction between SCA1[82Q] and Rora and
support the idea that loss of Rora function enhances
ATXN1[82Q] pathogenicity.
ATXN1 Interacts with the Nuclear Hormone
Coactivator
To gain insight into the molecular means by which mutant
ATXN1 disrupts RORa-mediated gene expression in Pur-
kinje cells, we examined the possibility that ATXN1 inter-
actswith RORa. First, ATXN1[30Q] and RORaproteins co-
localized within the nuclei of Purkinje cells by confocal
microscopy (Figure S2).
To examine whether this reflected a biochemical in-
teraction between endogenous ATXN1 and RORa, we
performed coimmunoprecipitation studies on cerebellar
lysates prepared from normal and Sca1/ mice. An
immunoprecipitation using an antibody against RORa
coimmunoprecipitated ATXN1 from a lysate prepared
from a normal mouse cerebellum. Conversely, RORa
coimmunoprecipitated with the anti-ATXN1 antibody
11750 (Figure 5A). Control immunoprecipitations using ly-
sates prepared from the cerebella of Sca1/mice failed
to bring down ATXN1 with the anti-RORa antibody or
RORa with the anti-ATXN1 antibody. GST-ATXN1 pull-
downs of in vitro transcribed/translated RORa were
used to assess whether ATXN1 and RORa might interact
directly. As show in Figure 5B, the results of this analysis
failed to demonstrate an interaction. None of the following
were able to able to pull down RORa above background
levels observed with GST alone: GST-Atx-30Q, 53Q, and
82Q.
The ability to coimmunoprecipitate ATXN1 and RORa
from cerebellar extracts in the absence of a direct interac-
tion between the two proteins indicates that ATXN 1 inter-
acts directly with a component of the RORa complex other
than RORa itself. At the promoter of Purkinje cell-specific
genes, RORa exists in a complex that includes many cor-
egulators (Gold et al., 2003). One protein found consis-
tently in the RORa complex at Purkinje cell-specific genes
is the coactivator Tip60 (Brady et al., 1999). Based on this
observation, we tested whether ATXN1 interacts with
Tip60. Coimmunoprecipitations using cerebella extracts
from wild-type mice indicated that endogenous ATXN1
and Tip60 do interact (Figure 5C). The ability of GST-
ATXN1 to pull down Tip60 fromwild-typemouse cerebella
extracts provided additional evidence that ATXN1 and
Tip60 interact (Figure 5D). Furthermore, the GST-ATXN1
pull down results suggested that as the length of the poly-
glutamine tract increased from 30Q to 53Q to 82Q the
amount of Tip60 pulled down increased. The effect ofell 127, 697–708, November 17, 2006 ª2006 Elsevier Inc. 701
Figure 3. Cerebellar RORa Is Depleted in
Mice Expressing a Disease-Causing
Form of ATXN1[82Q]
(A) Western blot analysis of RORa in protein ex-
tracts prepared from SCA1 mice. RORa levels
are normalized to a-tubulin. Lane 1, a wild-
type FVB/n mouse; lane 2, a mouse expressing
theK772TATXN1[82Q] variant; Lane 3, amouse
null for endogenous Sca1; lane 4, an affected
12 week old gene-on conditional SCA1[82Q]
mouse; lane 5, a conditional SCA1[82Q] mice
where the gene was on for 12 weeks and turned
off for 2 days and 10 days (lane 6); lane 7, an
unaffected 12 week old mouse expressing
SCA1[30Q]; lane 8, a sg/sg mouse.
(B) Immunofluorescent staining of RORa in the
cerebellar cortex of a 12 week old gene-on
SCA1[82Q] mouse.
(C) Immunofluorescent staining of RORa in the
cerebellar cortex of a 12 week old gene-on/5
day gene-off SCA1[82Q] mouse. Section was
simultaneously stained with antibodies against
RORa (red) and Purkinje cell-marker calbindin
(green).
(D) Northern blot analysis of Rora mRNA
(mean±SEM) levels inmurinecerebellar extracts
from 12 week-old wild-type (FVB) mice, ATXN1
transgenic mice expressing wild-type ATXN1
(SCA1[30Q]) or mutant ATXN1 (SCA1[82Q]),
Sca1/, and staggerer mice (sg/sg). Statisti-
cal significance was assessed using a one-
way ANOVA test followed by a Tukey HSD
test when necessary.
(E) Recovery of cerebellar RORa protein levels (western-blot data from A) and RoramRNA levels in SCA1[82Q] transgenic mice where the transgene
was on for 12 weeks (12 wks on-hatched bars), compared to protein and mRNA levels in mice where the SCA1[82Q] transgene was expressed for
12 weeks and turned off for 2 days (2d off, solid bars). Mean ± SEM.the ATXN1 polyglutamine tract length on its interaction
with Tip60 was also assessed using coimmunoprecipita-
tions from transfected tissue culture cell extracts.
Figure 5E shows that more ATXN1[82Q] was coimmuno-
precipitated with Tip60 than was ATXN1[30Q], providing
further evidence for a polyglutamine effect on the interac-
tion of ATXN1 with Tip60.
To assess if ATXN1 and Tip60might interact directly, we
utilized GST-ATXN1 pull-downs of in vitro transcribed/
translated Tip60. In contrast to the results obtained
when this approach was used to assess the interaction702 Cell 127, 697–708, November 17, 2006 ª2006 Elsevier Incof ATXN1 with RORa, Figure 5F shows that GST-ATXN1
was able to pull down in vitro transcribed/translated
Tip60. However, this analysis failed to provide evidence
of a polyglutamine tract effect. When the amount of
GST-ATXN1 was taken into account, GST-ATXN1-
30Q, -53Q, and -82Q appeared to interact withTip60
equally.
In light of the evidence that ATXN1 interacts directly with
Tip60, the regions of ATXN1 responsible for this interac-
tion were mapped. We generated a series of constructs
encoding FLAG-tagged fragments that spanned theFigure 4. Partial Loss of RORa Enhances
Pathogenicity of ATXN1[82Q] In Vivo
(A) Northern blot of cerebellar mRNA from B05
transgenic mice, B05/B05:staggerer (sg) het-
erozygous mice and B05/+:Rora wild-type
mice.
(B) Molecular layer thickness (mean ± SEM) at
the primary fissure (see Figure 2D) is reduced
at both 20 (p = 0.01) and 24 (p = 0.013) weeks
of age in B05/B05:staggerer (sg) heterozygous
mice compared to B05/+:Rora wild-type mice.
Statistical significance was determined using
a student’s t test..
Figure 5. Interaction of ATXN1 with
RORa and Tip60
(A) Coimmunoprecipitation of endogenous mu-
rine ATXN1 and RORa performed on cerebellar
protein extracts prepared from either a wild-
type FVB/n mouse or a Sca1/. Panel 1B,
anti-RORa immunoprecipitation followed by
western blotting with anti-ATXN1. Panel 2B,
Anti-ATXN1 immunoprecipitation followed by
western blotting with anti-RORa.
(B) GST-ATXN1 pull-down experiments of
in vitro transcribed/translated radio-labeled
RORa performed with ATXN1[30Q],
ATXN1[53Q], and ATXN1[82Q].
(C) Immunoprecipitations were performed on
cerebellar protein extracts prepared from ei-
ther a wild-type FVB/n mouse or a Sca1/.
Panel 1 depicts the amount of ATXN1 obtained
with an anti-Tip60 immunoprecipitation. Panel
2 depicts the amount of Tip60 obtained with
an anti-ATXN1 immunoprecipitation.
(D) GST-ATXN1 fusion proteins with glutamine
repeats of 30Q, 53Q, and 82Q were used to
pull down Tip60 from a cerebellar lysate pre-
pared from a wild-type FVB/n mouse.
(E) Coimmunoprecipitation of ATXN1 with
Tip60 from extracts of transfected COS-1 cells.
COS-1 cells were transfected with Tip60 and
either wild-type ATXN1[30Q] or mutant
ATXN1[82Q]. Upper panel is a western blot
analysis of RORa expression levels using an
anti-Xpress antibody. The middle panel is
a western blot analysis of ATXN1 expression
using the anti-ATXN1 antibody 11750. The
lower panel depicts the amounts of
ATXN1[30Q] and ATXN1[82Q] coimmunoprecipitated with RORa. Normalized quantifications are shown.
(F) GST-ATXN1 pull down of in vitro transcribed/translated radio-labeled Tip60. Pull-down experiments were performed with ATXN1[30Q],
ATXN1[53Q], and ATXN1[82Q]. The position of radiolabeled Tip60 is indicated.length of wild-type ATXN1 (Figure 6A). These constructs
were cotransfected with Tip60 into COS cells. As shown
in Figure 6B, the results reveal that amino acids 425–547
of ATXN1 have a critical role in ATXN1’s interaction with
Tip60. The two fragments of ATXN1 containing amino
acids 425–547, fragment III and IV, interacted with Tip60
at least as well as intact ATXN1[30Q] did. In contrast, frag-
ments lacking this portion of ATXN1 interacted to a lesser
extent with Tip60 than did full-length ATXN1[30Q]. Nota-
bly, these include the N-terminal 360 amino-acid fragment
containing the polyglutamine stretch and the C-terminal
fragment spanning amino acids 568–816 containing the
AXH domain (Chen et al., 2004).
Although the N-terminal 360 amino-acid fragment con-
taining a wild-type polyglutamine stretch (30 residues) did
not interact strongly with Tip60, the same fragment con-
taining a mutant polyglutamine stretch (82 residues) did
interact with Tip60 (Figure 6C). This may be because two
regions of full-length and properly folded ATXN1 are in-
volved in the interaction with Tip60. It is also possible
that the self-association or aggregation properties of the
exposed polyglutamine stretch leads to a detectable inter-
action with Tip60 through a nonspecific effect. Regard-
less, deciphering relevance of the polyglutamine-lengtheffect on the interaction between Tip60 and the N-terminal
fragment of ATXN1 is complicated by the absence of
a polyglutamine-length effect in GST pull downs from
in vitro translated Tip60 experiments.
DISCUSSION
We demonstrate that delaying expression of mutant
ATXN1 until completion of cerebellar maturation dramati-
cally reduced the susceptibility of adult Purkinje cells to
mutant ATXN1-induced neurodegeneration. We propose
that the molecular mechanism employed by mutant
ATXN1 to influence cerebellar development and induce
neurodegeneration in adult Purkinje cells is its ability to in-
duce the loss of RORa from Purkinje cell nuclei. This leads
to a reduced expression of RORa-mediated genes that
are critical for Purkinje cell development and function.
Expression of Rora begins embryonically around day
E14.5 (Nakagawa et al., 1997), while endogenous Sca1 is
first detectable at the beginning of postnatal week 2 (Banfi
et al., 1996). Expression of these two genes overlaps dur-
ing a substantial portion of postnatal cerebellar develop-
ment in themouse. Throughout the first 3 postnatal weeks,
the cerebellum increases in size by 1000-fold andCell 127, 697–708, November 17, 2006 ª2006 Elsevier Inc. 703
undergoes a series of dramatic developmental changes to
establish its adult structure and function (Goldowitz and
Hamre, 1998). During this period, the external granule layer
seeds the internal granule layerwith granule cells, andPur-
kinje cells mature, elaborating their dendritic trees and
forming synapses with granule cells. This is also the time
when the major inputs into the cerebellar cortex arise:
climbing fiber inputs to Purkinje cells from the inferior olive
and the mossy fiber inputs to the granule cells.
Figure 6. Mapping the Region of ATXN1 that Interacts with
Tip60
(A) Diagram of the deletion constructs used to map the interacting
region of ATXN1 with Tip60. I contains the polyQ tract (amino acids
1–360). III contains the SAD region of ATXN1 (amino acids 250–547).
IV contains the SAD and AXH region (amino acids 425–689). V contains
the AXH and NLS region of ATXN1 (amino acids 568–816).
(B) Top panel depicts coimmunoprecipitation of ATXN1[30Q] with M2
agarose beads and probed with anti-Tip60. Middle and lower panel
depict whole cell lysate probed with anti-FLAG or anti-Tip60 antibody.
(C) Comparison of the amount of Tip60 coimmnunoprecipitated with
full-length ATXN1[82Q] and with fragment I of ATXN1[82Q].704 Cell 127, 697–708, November 17, 2006 ª2006 Elsevier IncInsight into the molecular components of Purkinje cell
development targeted by mutant ATXN1 came from a mi-
croarray analysis of gene expression in the SCA1 mice.
Previous results from subtractive cDNA cloning and mi-
croarray-based gene expression profiling studies indi-
cated that genes whose products have a role in calcium
and/or glutamate signaling were downregulated prior to
the onset of symptoms in SCA1[82Q] mice (Lin et al.,
2000; Serra et al., 2004). Efforts to understand the physi-
ological basis of these results were complicated by the
fact that in many instances the genes identified had op-
posing effects on signaling. The critical step in linking
many of the genes downregulated in SCA1[82Q] mice
came upon comparing the SCA1 microarray data with
similar data obtained using the staggerer mouse (Gold
et al., 2003). Staggerer (sg/sg) mice have a deletion of
Rora, encoding the retinoid-related orphan nuclear-re-
ceptor transcription factor RORa (Hamilton et al., 1996).
RORa is highly expressed by Purkinje cells (Ino, 2004),
and its loss blocks Purkinje cell maturation (Landis and
Sidman, 1978; Hatten and Messer, 1978), resulting in
a congenital ataxia and hypoplastic cerebellum.
Many of the RORa-mediated genes whose expression
wasdecreased inSCA1[82] cerebella are highly expressed
byPurkinje cells (Figure S3).What’smore, loss-of-function
mutations for several of thesegenes result in anataxic phe-
notype. For example, mice with targeted mutations in
Calb1 (Airaksinen et al., 1997), Itpr1 (Matsumoto et al.,
1996), Rora (Hamilton et al., 1996; Dussalt et al., 1998;
Steinmayr et al., 1998), Slc1a6 (Huang et al., 2004), and
Grm1 (Aiba et al., 1994; Ichise et al., 2000) develop ataxia.
In addition, dominant-negativemutations in the humanho-
molog ofSpnb3 cause spinocerebellar ataxia type 5 (Ikeda
et al., 2006). These results provide strong support that the
SCA1/staggerer overlapping set of genes encode proteins
important for Purkinje cell function, consistent with a re-
duction in their expression having a role in SCA1.
Our data showed that a disease-causing formofATXN1-
consistently induced the depletion of RORa from Purkinje
cells. A subtle decrease in RORawas seen, by immunoflu-
orescence, in mice overexpressing wild-type SCA1[30Q].
This is of interest given that SCA1[30Q] overexpressing
mice do have a very mild altered phenotype (Fernandez-
Funez et al., 2000). Importantly, no decrease in RORa
was detectable in mice overexpressing a form of mutant
ATXN1 that fails to cause disease due to the presence of
a nonfunctional nuclear localization signal (NLS), or in
Sca1/ mice that lack expression of endogenous
ATXN1. This last observation is key in that it demonstrates
that the effect on RORa levels is a dominant property of
ATXN1[82Q]. Finally, the conditional mouse model of
SCA1, where RORa levels were restored within just a few
days of turning off the expression of mutant ATXN1, pro-
vides additional insight into the possible connection be-
tween RORa and SCA1. First, recovery of RORa preceded
the recovery of the morphological and neurological symp-
toms in these mice (Zu et al., 2004), suggesting that per-
haps morphological and neurological recovery is linked.
to restoration of RORa. Second, we found that recovery of
RORa protein occurred in the absence of a recovery of
RoramRNA. This provides evidence that the effect of mu-
tant ATXN1onRORa expression is at least in part due to an
effect on RORa protein stability.
Although themeans bywhich expansion of the polyglut-
amine tract in ATXN1 alters RORa stability in vivo is un-
clear, results of protein-protein interaction studies indi-
cate that the relationship between RORa and ATXN1
extends to the molecular level. RORa and ATXN1 could
be coimmunoprecipitated from cerebellar extracts pre-
pared from wild-type mice, yet GST-ATXN1 was unable
to pull down in vitro transcribed/translated RORa. Though
either GST-ATXN1 or in vitro transcribed/translated RORa
could lack a posttranslational modification critical for the
two to interact directly, a more likely conclusion is that
RORa and ATXN1 do not interact directly. Rather, their
ability to be coimmunoprecipitated from cerebellar ex-
tracts reflects that they both can be part of the same com-
plex. There is evidence that RORa (Gold et al., 2003) and
nuclear receptors in general function as part of a number
of coregulatory complexes that include coactivators and
correpressors (Perissi and Rosenfeld, 2005). The Tat-in-
teracting protein, Tip60, is one nuclear-receptor coactiva-
tor (Brady et al., 1999) that has been placed in the RORa
complex at the promoters of Purkinje cell-specific genes
(Gold et al., 2003). Our data showing an interaction be-
tween ATXN1 and RORa and a direct interaction between
ATXN1 and Tip60 point to the existence of a complex con-
taining ATXN1, RORa, and Tip60. This is consistent with
and adds to the concept that RORa and Tip60 are within
the same complex.
A complex containing ATXN1, RORa, and Tip60, in
which there is a direct interaction between ATXN1 and
Tip60, provides a situation whereby mutant ATXN1 might
induce the destabilization of RORa. In transfected COS-1
cells, RORa is a short-lived protein (Moraitis and Gigue`re,
2003). Perhaps RORa is stabilized when it is located in
a complex with Tip60. In this case, one could envision
that this complex is disrupted and RORa destabilized by
virtue of a direct interaction between mutant ATXN1 and
Tip60. It is of interest, therefore, that our data on the inter-
action of ATXN1 and Tip60 showed some indication of
a polyglutamine effect (Figures 6D and 6E).
Amino acids 425–547 of ATXN1 were shown to mediate
its interaction with Tip60. Previously, this region of ATXN1
was designated as the self-association region based on its
ability to promote the self association of ATXN1 in a yeast
two-hybrid system (Burright et al., 1997). Interestingly,
mice overexpressing in their Purkinje cells a version of
ATXN1[82Q] lacking residues 425–547 developed a dis-
ease in which progression was slowed dramatically (Skin-
ner et al., 2002). This is in agreement with interactions me-
diated by this region of ATXN1, perhaps with Tip60/RORa,
contributing to disease in vivo.
Thus far, several proteins that interact with ATXN1 have
been identified as possible mediators of SCA1 pathogen-
esis. These include PQBP, SMRT, BOAT, and Gfi-1C(Okazawa et al., 2002; Tsai et al., 2004; Tsuda et al.,
2005). The portion of ATXN1 implicated in its interaction
with Tip60 does not include the polyglutamine tract that
mediates the interaction between ATXN1 and PQBP, nor
does the Tip60 interacting region include the AXH domain
of ATXN1, an OB-folding domain shared by ATXN1 and
the transcriptional repressor HBP-1 (de Chiara et al.,
2003; Chen et al., 2004). The AXH domain does mediate
the interaction of ATXN1 with RNA (Yue et al., 2001) as
well as with SMRT (Tsai et al., 2004; Mizutani et al.,
2005) and Gfi-1 (Tsuda et al., 2005). Gfi-1 and Tip60/
RORa are unique in that they fulfill several criteria consis-
tent with having a role in SCA1 pathogenesis. Thus, it is
likely that ATXN1 participates in more than one pathway
in Purkinje cells, with each pathway making some contri-
bution to SCA1 pathogenesis.
Taking our in vivo and in vitro observations together with
those of other studies, we propose that a critical determi-
nant of SCA1 is the developmental timing of mutant
ATXN1 expression. Moreover, this developmental contri-
bution to SCA1pathogenesis likely is the result of a disrup-
tion of RORa-mediated gene expression by mutant
ATXN1. Thus the developmental processes impacted by
mutant ATXN1 would be those mediated by RORa and
take place when Sca1 and RORa are both expressed by
Purkinje cells. One attractive candidate is the develop-
ment of the stereotypical dendritic tree of the Purkinje
cell. Timing of Purkinje cell dendritic development over-
laps with the period of RORa/ATXN1 coexpression (Ar-
mengol and Sotelo, 1991). Recently, Boukhtouche et al.
(2006) reported that RORa plays a crucial role in the devel-
opment of the Purkinje cell dendritic tree. They suggested
that RORa has a role in the remodeling that occurs early in
the development of the Purkinje cell dendritic tree. This
disruption likely extends into the adult since heterozygous
staggerer mice have an age-dependent atrophy of their
Purkinje cell dendrites (Hadj-Sahraoui et al., 2001). De-
spite the apparent developmental component to the
course of SCA1 in Purkinje cells, no obvious structural ab-
normalities of dendrite development have been noted in
the SCA1 mice (Clark et al., 1997). This suggests that
the SCA1-associated disruption in Purkinje cell develop-
ment is likely to be subtle.
In summary, we conclude that a decrease of RORa-me-
diated gene expression during development is an impor-
tant factor in the susceptibility of Purkinje cells to SCA1.
What might be the relevance of these observations to
SCA1 in humans and perhaps neurodegenerative disease
more generally? We suggest this work demonstrates that
a failure of neurons to develop fully, even in the absence of
having an immediate effect on phenotype, can result in
a decreased ability of adult neurons to handle an insult.
EXPERIMENTAL PROCEDURES
DNA Microarray Analysis
Microarray data was obtained as described (Serra et al., 2004) and
analyses performed using Gene Data Expressionist Version 5, Refinerell 127, 697–708, November 17, 2006 ª2006 Elsevier Inc. 705
5.0.6, Analyst 5.0.6. Criteria used to detect differences in gene expres-
sion were p values% 0.05 and a fold changeR 1.5.
Transfection and Immunoprecipitation Using Tissue-Culture
Cells
Briefly, we transfected COS-1 cells with pcDNA Amp-flag-ATXN
1[30Q] or [85] and either pcDNA3.1 His ARORf or Tip60with Lipofect-
amine Plus (Invitrogen). Cells were harvested 48 hr posttransfection
and lysed in RIPA buffer. Immunoprecipitations were performed using
either the anti-Xpress antibody (Invitrogen) or anti-ATXN 1 antibody
11750 (Servadio et al., 1995) (see Supplemental Data). The following
antibodies were used for western blot analysis: anti-ATXN 1 antibody
11750, anti-Tip60 antibody (07-038 Upstate), or anti-RORf antibody
(SC-26380 Santa Cruz) (See Supplemental Experimental Procedures).
Protein was detected with Western Lightning Chemiluminescence
(Perkin Elmer Life Sciences) and quantified by densitometry using
the BioRad Gel Doc GS700 system.
Immunoprecipitation and Western Blot Analysis of Cerebellar
Extracts
Cerebellar homogenates were prepared from each genotype, and im-
munoprecipitations were performed using either the anti-ATXN 1 anti-
body 11750 (Servadio et al., 1995), anti-RORa sc-6062 (Santa Cruz,
CA), or anti-Tip60 sc-25378 (Santa Cruz, CA). Subsequent western
blot analysis was performed with the anti-ATXN 1 antibody 11750,
with anti-RORa (SC-26380 at 1:500; Santa Cruz, CA), or with antiTip60
(SC-25378 at 1:1000; Santa Cruz, CA) (see Supplemental Data).
Immunofluorescence
Immunofluorescent staining of mouse cerebellum was performed as
previously described (Skinner et al., 1997). Briefly, epitopes were un-
masked using 0.01 M urea. The sections were blocked for 1 hr in 2%
normal donkey serum and incubated for 48 hr with the primary anti-
bodies either anti-ATXN 1 antibody 11750 or 11NQ, anti-RORf (SC-
6062) or anti-calbindin (SC-9848). The sections were washed in phos-
phate-buffered saline (PBS) and incubated for 48 hr with secondary
antibody conjugated to Alexa Fluor 488 or Cy 3. Confocal images
were collected (Bio-Rad, MRC 1000) with the collection parameters
held constant. For further detail, see Supplemental Data.
Quantification of RORa in Purkinje cells was measured using Image
Pro Plus analysis software (Media Cybernetics’ Corporation, USA).
Twelve bit confocal images were collected (Bio-Rad, MRC 1000)
from three different animals in each genotype, and the average density
of the mean was determined for approximately 50 Purkinje cells and
interneurons from each animal. The average density of the mean of
RORa in Purkinje cells was divided by the average density of the
mean in interneurons, and the ratios were compared to FVB/n. Levels
of RORa in interneurons were used as a control.
In Vitro Transcription/Translation GST Pull-Down Assay
Full-length and partial human ATXN1 cDNAs were cloned into pGEX
family vectors (Amersham Biosciences) and expressed in E. coli
BL21(DE3) cells. Fusion proteins in the supernatants were separated
from bacterial proteins on a glutathione agarose column (Molecular
Probes). Fusion-protein degradation products were removed by gel-
filtration chromatography on a 300X 9 mm Superdex 200 column
(Amersham Biosciences). For a pull-down experiment, 8–20 mg of fu-
sion protein was pre bound to 20 ml packed glutathione agarose with
1 ml binding buffer (120 mM NaCl, 20 mM Tris-Cl pH 8.0, 1 mM DTT,
0.05% NP-40) for 30 min at room temperature. After binding, the su-
pernatant was removed and replaced with 20 ml binding buffer and
11 ml of an in vitro transcription/translation reaction prepared accord-
ing to the directions of the TnT Coupled Reticulocyte Lysate System
(Promega) using [35S] methionine (Perkin Elmer) and pCDNA3.1 ex-
pression constructs for either mouse RORa or XPRESS- and His-
tagged human Tip60. Binding was allowed to proceed at room temper-
ature for 20 min with occasional flicking to agitate the beads. Beads706 Cell 127, 697–708, November 17, 2006 ª2006 Elsevier Incwere washed 4 times in binding buffer, and protein was eluted with
30 ml 2X sample buffer (125 mM Tris pH 6.8, 2% sodium dodecylsul-
fate, 20% glycerol, 160 mM DTT, and 2 mM EDTA with 0.01% brom-
phenol blue).
GST Pull-Down from Cerebella Extracts
SCA1[30Q, 53Q, and 82Q] cDNAs were cloned into pGEX-2T (Amer-
sham) to generate GST-ATXN1 fusion proteins and expressed in E.
coli DH5. The fusion proteins were isolated from cell pellets by adding
200 ml of Cell Lysis Reagent (MagneGST Pull-Down System, Prom-
ega), 2 ml of RQ1 Rnase-Free Dnase and 1X protease inhibitor (Roche)
with incubation at room temperature for 20–30 min on a rotating plat-
form. The amount of bacterial extract used in each experiment was
determined based on a Simply Blue SafeStain (Invitrogen) stained
4%–12% Nupage Bis-Tris polyacrylamide gel to assess levels of fu-
sion-protein expression. The bacterial extracts were bound to 20 ml
of MagneGST Particles (Promega) in MagneGST Binding/wash
Buffer and incubated for 30 min at room temperature on a rotating
platform. Beads were washed 3 times in MagneGST Binding/wash
Buffer. After the last wash, the particles were resuspended in 20 ml of
MagneGST Binding/wash Buffer. To each 5 ml aliquot of particles
carrying GST-fusion protein (or GST control), 50 mg of cerebellar ex-
tract, 20 ml 10%BSA, and MagneGST Binding/wash Buffer were
added to a final volume of 200 ml and incubated for 2 hr at 4C with
mild rotation. Immune complexes were washed 5 times with 400 ml
of MagneGST Binding/wash Buffer. Beads were resuspended in 1X
SDS sample buffer for 5 min at room temperature, removed and the
supernatant was boiled for 5 min, run on a 4%–12% Nupage Bis-Tris
polyacrylamide gel (Invitrogen), and transferred to nitrocellulose mem-
brane (Protran, Schleicher and Schuell). The membrane was probed
with anti-Tip60 antibody at 1:1000 (SC-25378; Santa Cruz, CA).
Deletion Constructs and Coimmunoprecipitation
SCA1 deletion constructs were cloned into CSII-CDF-EF-3xFLAG-
MCS (gift from Nik Somia). This vector contains three tandem flag epi-
tope sequences at the amino terminus. Full-lengthSCA1 cDNAwas di-
gestedwith Sal I, treatedwith Klenow to fill in and digested with EcoR I,
and then cloned into the EcoR I/Hpa I sites of CSII-CDF-EF-33 FLAG-
MCS. Creation of the SCA1 fragments is described in Supplemental
Data. COS-1 cells were cotransfected with the SCA1 constructs and
pcDNA 3.1 HisA-Tip60 using lipofectamine plus reagent (Invitrogen)
and harvested 48 hr posttransfection. Cell lysates were collected,
and coimmunoprecipitations were performed using the FLAG-IP kit
(catalog # FLAGIPT1-1KT, Sigma) as per instructions. Immunoprecip-
itated samples were run on 4%–12% Nupage Bis-Tris polyacrylamide
gels, transferred to nitrocellulose membrane, and probed with anti-
Tip60 antibody at 1:1000 (#07-038 Upstate). Total lysate controls
were probed with anti-Flag-HRP antibody at 1:20,000 (#A8592 Sigma)
or anti-Tip60 antibody.
Statistical Analysis
Data were expressed as the mean ± SEM. Data were analyzed using
either a student’s t test for the comparison of two groups or a one-
way anova for the comparison of more than two groups. A Tukey’s
Honestly Significant Difference (HSD) Post Hoc Test was performed
when necessary.
Supplemental Data
Supplemental Data include three figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at
http://www.cell.com/cgi/content/full/127/4/697/DC1/.
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